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Background: Immune checkpoint blocker (ICB) has shown significant clinical activity in
melanoma. However, there are no clinically approved biomarkers to aid patient selection.
We aimed to identify patients with advanced or metastatic melanoma who are likely to
benefit from ICB monotherapy using easily accessible clinical indicators.
Materials and Methods: We retrospectively reviewed the records of 134 patients with
advanced or metastatic melanoma who received ICB monotherapy between 2014 and
2018. Prognostic factors of overall survival (OS) and progression-free survival (PFS) were
determined using Cox regression analysis.
Results: During the median follow-up of 13.7 months, the median OS and PFS were 18.4
and 3.4 months, respectively. Visceral/central nervous system (CNS) metastasis (OS:
adjusted hazards ratio [HR], 1.82; p=.014; PFS: HR, 1.59; p=.024), lymphopenia (<1000
cells/µL) within 3 months (OS: HR, 1.89, p=.006; PFS: HR, 1.70; p=.010), and elevated
baseline lactate dehydrogenase (LDH) level (OS: HR, 2.61; p<.001; PFS: HR, 2.66;
p<.001) were independent prognostic factors for both poor OS and PFS. Development of
immune-related adverse events (irAE; e.g., hypothyroidism or vitiligo) within 6 months
showed a trend toward better OS in multivariable analysis (HR, 0.37; p=.058). Patients
with normal LDH levels and no visceral/CNS metastasis had a substantially better OS than
the others (median, 40.4 vs. 13.6 months; p<.001). Among others, patients who
developed irAE within 6 months achieved long-term OS (median, 43.6 vs. 13.1 months;
p=.008). A decision tree was suggested using four risk factors, and the risk stratification
provided significant distinction between the survival curves.May 2021 | Volume 11 | Article 6597541
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Frontiers in Oncology | www.frontiersin.orgConclusion: The four easily accessible clinical indicators associated with better
treatment outcomes after ICB monotherapy in patients with advanced or metastatic
melanoma were LDH level, the extent of disease, lymphopenia, and irAE. The combined
use of these indicators can be clinically useful in improving risk stratification of patients
treated with ICB monotherapy.Keywords: lymphopenia, overall survival, predictor, melanoma, immune checkpoint blockadeINTRODUCTION
The recent emergence of cancer immunotherapies has led to a
significant shift in the clinical management of metastatic
melanoma (1). Prior to 2011, patients with advanced or
metastatic melanoma only had palliative treatment solutions that
offered little to no survival benefit. Patients now benefit from novel
immune checkpoint blockers (ICBs)—anti-cytotoxic T-
lymphocyte protein 4 (CTLA-4) and anti-programmed cell death
protein 1 (PD-1). In recent years, several randomized controlled
phase III trials have shown the efficacy and safety of ICBs. The
CheckMate 066 trial showed that nivolumab was associated with
significant improvements in overall survival (OS) and progression-
free survival (PFS) compared with dacarbazine in treatment-naïve
patients who had metastatic melanoma without a BRAF mutation
(2). Patients with advanced melanoma who received ipilimumab
plus dacarbazine had better OS than those who received
dacarbazine alone (3). Patients with metastatic melanoma who
received ipilimumab plus gp100 peptide vaccine had improved OS
than those who received gp100 alone (4). Furthermore, the
CheckMate 067 and KEYNOTE-006 trials showed that
nivolumab and pembrolizumab, respectively, improved treatment
outcomes more than ipilimumab (5, 6). The clinical effects of
ICBs are most apparent in patients with metastatic or advanced
melanoma (2–7). However, response rates are modest with ICB
monotherapy. The response rates for ipilimumab and
pembrolizumab or nivolumab range from 11% to 19% (5, 7) and
33% to 44% (2, 5, 6), respectively. We have previously reported that
the objective response rate of ICB monotherapy in South Korean
patients with melanoma is 15% (8).
Currently, there are no clinically approved biomarkers to aid
patient selection for immunotherapy in melanoma. Recent
studies have been focusing on identifying biomarkers that
could predict patient response prior to treatment initiation or
very early during the treatment course to maximize therapeutic
efficacy, minimize medical costs, and overcome side effects (9).
In recent years, studies have been conducted on biomarkers
using omics technologies such as next-generation sequencing
and mass cytometry. With these novel markers, more easily
accessible clinical indicators that can be identified by a simple
blood test or routine clinical examination may ideally aid in
therapeutic decision making. These indicators may be useful
while integrating omics technologies in actual practice. Thus, we
sought to identify patients with advanced or metastatic
melanoma who are likely to benefit from ICB monotherapy
using easily accessible clinical indicators.2
MATERIALS AND METHODS
Patient Population
We retrospectively identified consecutive patients with advanced
or metastatic malignant melanoma treated with ICBs between
2014 and 2018 at Yonsei Cancer Center, Seoul, Republic of
Korea. Data regarding patient demographics, treatments and
related parameters, and outcomes were obtained from the
medical records. The inclusion criteria were as follows: age ≥18
years; pathologically confirmed malignant melanoma; at least one
cycle of treatment with a CTLA-4 inhibitor or a PD-1 inhibitor;
and availability of follow-up images for the assessment of
treatment response. The tumors were clinically classified
according to the extent of surrounding solar elastosis and the
anatomical site as chronic sun-damaged melanomas and non-
chronic sun-damaged melanomas (acral, mucosal, and uveal). The
use of palliative radiotherapy during treatment was evaluated for
all patients. For advanced or metastatic malignant melanoma,
palliative radiotherapy was administered for symptomatic
metastasis after a thorough discussion with a multidisciplinary
melanoma team, including medical oncologists, radiation
oncologists, dermatologists, ophthalmologist, and pathologists.
Combination therapy with an ICB and radiotherapy was defined
as the administration of radiotherapy during ICB therapy or
within 3 months before and after ICB therapy. This study was
approved by our Institutional Review Board (4–2019–0796). The
requirement for informed consent was waived for this
retrospective study.
Outcome Assessment
The follow-up period was defined as the interval between the first
ICB administration and the date of the last visit or death. PFS
was defined as the time from ICB administration to disease
progression or death, and OS was defined as the time from ICB
administration to death from any cause. The best radiological
response was assessed based on the immune Response
Evaluation Criteria in Solid Tumors.
Adverse events were recorded using the Common Terminology
Criteria for Adverse Events, version 4.03. Because immunotherapy-
related hypothyroidism or vitiligo is associated with favorable
treatment outcomes in patients with melanoma (10, 11) and
treatment-related lymphopenia is associated with poor treatment
outcomes in various types of cancer including melanoma (12–14),
we included these adverse events in the subsequent analyses to
identify prognostic factors. The extent of disease was classified
using the M stage of cutaneous melanoma in the 8th edition ofMay 2021 | Volume 11 | Article 659754
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including muscle and/or nonregional lymph nodes, M1b indicates
metastasis to the lungs, M1c indicates metastasis to non-central
nervous system (CNS) visceral sites, and M1d indicates metastasis
to the CNS. Patients were stratified into groups with visceral or
CNS metastasis (M1c or d) and others.
Statistical Analysis
Cox’s regression model was used for univariable and
multivariable analyses of PFS and OS. Factors with a P-value
of <0.1 in univariable analyses were included in multivariable
analysis. Survival analyses were performed using the Kaplan–
Meier method, and the log-rank test was used for the intergroup
comparisons. A p-value of <0.05 was considered statistically
significant. Statistical analyses were performed using SPSS
(version 25; IBM Inc., Armonk, NY, USA).RESULTS
Patient, Tumor, and Treatment
Characteristics
The patient, tumor, and treatment characteristics are summarized
inTable 1. The median age at referral for ICB therapy was 60 years
(range, 18–88 years). Of the 134 patients, 107 (79.9%), 22 (16.4%),
and 5 (3.7%) were diagnosed with acral/mucosal, uveal, and
chronic sun damage subtypes, respectively. The extent of disease
was as follows: locally unresectable in 8 (6%) patients; skin, soft
tissue, and/or regional nodal metastasis in 32 (24%) patients; lung
metastasis in 18 (13.4%) patients; non-CNS visceral organ
metastasis in 68 (50.7%) patients; and CNS metastasis in 8 (6%)
patients. The median baseline lactate dehydrogenase (LDH) level
was 215 U/L (range, 134–3002 U/L). The baseline LDH level
was elevated in 45 (33.6%) patients. The median number of ICB
cycles was 3 (range, 1–33). Pembrolizumab (n=96, 71.6%) was the
most commonly used medication, followed by ipilimumab (n=31,
23.1%) and nivolumab (n=7, 5.2%). Combination therapy with an
ICB and palliative radiotherapy was used in 63 (47.0%) patients.Immunotherapy-Related Adverse Events
During follow-up, grade 1/2 immunotherapy-related
hypothyroidism and vitiligo developed in 9 (6.7%) and 15
(11.2%) patients, respectively, of which 6 (4.5%) and 8 (6.0%)
patients manifested the adverse events within 6 months,
respectively. Of the nine patients who developed immune-
related hypothyroidism after ICB monotherapy, all patients were
treated with levothyroxine and three were additionally treated
with glucocorticoids. The OS and PFS were not significantly
different between the patients who received glucocorticoids and
those who did not (median OS, 22.4 months vs. not reached;
p=.271; median PFS, 2.4 months vs. 2.8 months; p=.807). Of note,
the published literature has shown that although the theoretical
risk that immunosuppression reduces antitumor efficacy has not
been proven, immunosuppression does carry additional risks that
clinicians should consider (15). Of the 15 patients who developed
immune-related vitiligo, none of them was treated for vitiligo.Frontiers in Oncology | www.frontiersin.org 3Other adverse events were grade 1/2 skin rash (n=7, 5.2%), grade
3/4 liver enzyme elevation (n=2, 1.5%), grade 3 thrombocytopenia
(n=1, 0.7%), and grade 1 pruritus (n=1, 0.7%). Within 3 months,
lymphopenia developed in 51 (38.1%) patients, of which 12 (9.0%),
19 (14.2%), 16 (11.9%), and 4 (3.0%) patients developed grade 1, 2,
3, and 4 lymphopenia, respectively.
Identification of Prognostic Factors
We conducted univariable and multivariable analyses for OS and
PFS using patient, tumor, and treatment characteristics and
immunotherapy-related adverse events (irAE) to identify
prognostic factors in patients with melanoma treated with ICB
(Table 2). In univariable analyses for OS, visceral or CNS
metastasis, high baseline LDH level, lymphopenia within 3
months, and hypothyroidism or vitiligo within 6 months were
significantly associated with OS (all P<0.05). Multivariable
analysis for OS revealed that visceral or CNS metastasis
(hazards ratio [HR], 1.82; 95% CI, 1.09–3.04; p=0.014), high
baseline LDH level (HR, 2.61; 95% CI, 1.59–4.28; p<0.001), and
lymphopenia within 3 months (HR, 1.89; 95% CI, 1.16–3.09;
p=0.006) were independent prognostic factors for OS.TABLE 1 | Patient, tumor, and treatment characteristics.
N=134







Chronic sun damage 5 (3.7)
BRAF mutation, n (%)
Wild type 93 (69.4)
V600 mutation 16 (11.9)
Unknown 25 (18.7)
Disease extent, n (%)
Locally unresectable status 8 (6)
Skin, soft tissue, regional nodal metastasis 32 (23.9)
Lung metastasis 18 (13.4)
Non-CNS visceral site metastasis 68 (50.7)
CNS metastasis 8 (6)
Baseline LDH, median (range), U/L 215 (134–3002)









Cycles of ICB, median (range) 3 (1–33)
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significance in multivariable analysis (HR, 0.37; 95%, 0.13–
1.04; p=0.058). The same factors were independent prognostic
factors for PFS. Visceral organ or CNS metastasis (HR, 1.59; 95%
CI, 1.06–2.39; p=.024), high baseline LDH level (HR, 2.66, 95%
CI, 1.71–4.13; p<0.001), and lymphopenia within 3 months (HR,
1.70; 95% CI, 1.13–2.54; p=.010) were independently associated
with poor PFS.
Additionally, the identified prognostic factors were evaluated
for their ability to predict the best radiological tumor response.
Twenty-four (17.9%) patients had an objective response
(complete or partial response). No visceral/CNS metastasis
[odds ratio (OR), 6.92; 95% CI, 2.40-19.96; p<.001] and
normal baseline LDH level (OR, 3.31; 95% CI, 1.05-10.38;
p=.040) significantly predicted objective response, while no
lymphopenia (OR, 1.28; 95% CI, 0.51-3.26; p=.599) and
immune-related adverse events (OR, 1.29; 95% CI, 0.33-5.01;
p=.717) did not predict objective response.
Survival Analysis
During the median follow-up of 13.7 months (range, 1.6–68.3
months), the median OS and PFS were 18.4 months [95%
confidence interval (CI), 14.2–22.6 months] and 3.4 months
(95% CI, 2.5–4.3 months), respectively. Using the identified risk
factors, we divided patients into subgroups and conducted
survival analyses. First, the extent of disease and baseline LDH
levels were used to define the patient subgroup because these two
factors can be identified prior to ICB administration. Patients
with no visceral/CNS metastasis and normal baseline LDH levels
were categorized into the favorable group (n=43) and the others
were categorized into the unfavorable group (n=84). TheFrontiers in Oncology | www.frontiersin.org 4favorable group had significantly better OS (median, 40.4 vs.
13.6 months; p<0.001) and PFS than the unfavorable group
(median, 6.5 vs. 2.8 months; p=0.001; Figure 1). Because OS and
PFS were relatively poor in the unfavorable group, it was
important to further identify the subgroup of patients who
may benefit from ICB therapy. Thus, we conducted the
subsequent survival analyses in the unfavorable group (n=84).
In the unfavorable group, the patients who did not develop
lymphopenia within 3 months (n=46) had a significantly better
OS (median, 18.3 vs. 11.4 months; p=.003) and PFS than those
who developed lymphopenia (median, 3.3 months vs. 2.0
months; p=.007; Figures 2A, B). In the unfavorable group, a
few patients who developed immune-related hypothyroidism or
vitiligo within 6 months (n=7) had exceptionally better OS than
those without such immune-related events (median, 43.6 vs. 13.1
months; p=.008), while PFS was not significantly different
(median, 8.6 vs. 2.8 months; p=.199, Figures 2C, D).
Among all patients, those who developed hypothyroidism
(n=6) and vitiligo (n=8) within 6 months had a median OS of
22.4 months and 43.6 months (p=.081) and a median PFS of 2.8
months and 8.6 months, respectively (p=.717).
Clinical Decision Tree Proposal
A clinical decision tree proposal based on the survival analysis is
shown in Figure 3A. Patients with normal baseline LDH levels
and no visceral/CNS metastasis (favorable group) had
exceptionally better OS and PFS than the others; hence, these
patients are most likely to benefit from ICB therapy. Among the
unfavorable group, patients without lymphopenia within 3
months had better OS and PFS; hence, these patients are more
likely to benefit from ICB therapy than those with lymphopenia.TABLE 2 | Analysis of factors associated with progression-free survival and overall survival.
Overall survival Progression-free survival
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (per 1 year increase) 1.01 (0.99–1.03) 0.563 0.99 (0.97–1.01) 0.328
Female (vs. Male) 1.04 (0.67–1.62) 0.867 0.95 (0.66–1.37) 0.778
Subtype
Uveal (vs. acral/mucosal) 1.39 (0.79–2.45) 0.258 0.84 (0.51–1.39) 0.505
Chronic sun damage (vs. acral/mucosal) 0.79 (0.19–3.23) 0.739 0.5 (0.16–1.61) 0.245
BRAF mutation
V600 mutation (vs. wild type) 0.66 (0.31–1.4) 0.282 1.66 (0.96–2.86) 0.068 1.13 (0.63–2.02) 0.692
Unknown (vs. wild type) 1.37 (0.77–2.42) 0.286 0.8 (0.49–1.33) 0.395 0.63 (0.36–1.09) 0.098
ICB type
Pembrolizumab (vs. ipilimumab) 0.92 (0.54–1.57) 0.769 0.76 (0.49–1.17) 0.211
Nivolumab (vs. ipilimumab) 0.72 (0.25–2.09) 0.547 0.46 (0.18–1.19) 0.108
No. of previous chemotherapy (per 1 increase) 1.06 (0.85–1.32) 0.618 1.2 (0.97–1.47) 0.089 1.20 (0.97–1.50) 0.099
Radiotherapy yes (vs. no) 1.29 (0.83–2.01) 0.264 0.94 (0.65–1.36) 0.746
Visceral organ/CNS metastasis yes (vs. no) 2.44 (1.5–3.97) <0.001 1.82 (1.09–3.04) 0.014 1.72 (1.17–2.52) 0.006 1.59 (1.06–2.39) 0.024
Baseline LDH elevation yes (vs. no) 3.51 (2.2–5.59) <0.001 2.61 (1.59–4.28) <0.001 3.03 (2.01–4.58) 0.000 2.66 (1.71–4.13) <0.001
Lymphopenia within 3 months yes (vs. no) 2.48 (1.57–3.93) <0.001 1.89 (1.16–3.09) 0.006 1.86 (1.28–2.73) 0.001 1.70 (1.13–2.54) 0.010
Hypothyroidism or vitiligo within 6 months yes (vs. no) 0.35 (0.14–0.87) 0.023 0.37 (0.13–1.04) 0.058 0.62 (0.33-1.16) 0.135 0.72 (0.36–1.42) 0.338May 2021 | Volume 11 | ArticleCI, confidence interval; CNS, central nervous system; HR, hazards ratio; ICB, immune checkpoint blocker; LDH, lactate dehydrogenase.659754
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hypothyroidism or vitiligo within 6 months had exceptionally
favorable OS; hence, these patients were classified as “late
responders.” The risk stratification provided significant
distinction between the Kaplan–Meier curves (Figure 3B).
Of the late responders, except 1 patient whose OS was 4.3
months, the other 6 patients had long-term OS, which ranged
from 23.5 to 68.3 months. The PFS of these patients ranged from
2.0 to 34.1 months. Four of them underwent heavy subsequent
treatments such as systemic chemotherapy and immunotherapy
as well as local therapy such as gamma knife surgery,
radiotherapy, and surgical resection. The profiles of the late
responders are shown in Supplementary Table 1.DISCUSSION
In this study, we identified four clinical indicators to identify
patients with advanced or metastatic melanoma who may benefit
from ICB monotherapy. These include baseline LDH level, the
extent of disease, lymphopenia, and irAE. Among the favorable
group who had normal baseline LDH level and no visceral/CNS
metastasis, we observed very prolonged OS (median, 40.4
months) even if all patients had advanced or metastatic
melanoma. Although patients were classified into the
unfavorable group, subgroups of patients who may have longer
OS can be sorted early during the treatment course using other
clinical indicators, such as lymphopenia and irAE. Baseline LDH
level, the extent of disease, and lymphopenia were independent
prognostic factors for both OS and PFS.
As response to immunotherapy can be achieved for only a
subset of patients, there is a crucial need to identify biomarkers to
predict the efficacy of anti-CTLA-4 or anti-PD-1 treatment or
identify a specific subset of patients who may benefit from
immunotherapy. Researchers have investigated many potentialFrontiers in Oncology | www.frontiersin.org 5biomarkers for immunotherapy in advanced or metastatic
melanoma patients using novel technologies, such as next-
generation sequencing, T-cell receptor profiling, and mass
cytometry (9). Among them, tumor mutations and neoantigen
load as well as the expression of immune-related genes in tumor
tissue and/or the presence of CD8+ T-cell infiltrates showed
significant correlations to response in large genetic and
transcriptional analyses of tumor tissue (16). The response
prediction would be more powerful if these high-technology
novel biomarkers are combined with clinical indicators which
can be obtained using non-invasive and easily accessible
techniques. The suggested clinical biomarkers in the current
study can be determined through a simple blood test or routine
clinical exam and are cost-effective and quickly identified. Thus, we
surmise that utilizing these easily accessible biomarkers will be of
clinical use to guide proper patient selection for immunotherapy.
In 2009, LDH was shown to be an independent predictor of
survival in melanoma and was therefore added to the AJCC
guidelines (17). Accelerated metabolism in cancer cells requires
increased glycolysis that produces elevated levels of LDH as a
byproduct, which is therefore a robust proxy to assess tumor
burden (18). In the context of immunotherapy, baseline LDH
level and visceral/CNS metastasis were both independent
prognostic factors in this study. This finding is consistent with
previous reports. A retrospective data from the Netherlands and
the United Kingdom also suggested that patients with metastatic
melanoma whose baseline serum LDH was greater than twice the
upper limit were unlikely to benefit from ipilimumab treatment
(19). A retrospective large cohort of advanced melanoma
patients also showed that elevated LDH and the presence of
liver metastasis predict poor response to anti-PD-1 therapy (20).
We also revealed that patients who developed lymphopenia
within 3 months after ICB initiation are associated with poor OS.
Lymphocytes are important mediators of ICB mechanism. Given
that circulating lymphocytes are the cells that eventually infiltrateA B
FIGURE 1 | (A) Overall survival and (B) progression-free survival in the favorable and unfavorable groups. The favorable group was defined as patients with no
visceral/CNS metastasis and normal baseline LDH level, and the unfavorable group was defined as other patients.May 2021 | Volume 11 | Article 659754
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treatment outcomes after immunotherapy. Similar to our
results, a retrospective analysis with melanoma patients treated
with ipilimumab also showed that increases in absolute
lymphocyte counts at 2–8 weeks and circulating CD4+ and
CD8+ T cells at 8–14 weeks were associated with positive
clinical outcomes (21).
In this study, 7% and 11% of patients developed
immunotherapy-related hypothyroidism and vitiligo, respectively,
of which 5% and 6% developed within 6 months, respectively.
Although irAE can present at any time, including after cessation of
ICB therapy, we confined the biomarker to the irAE occurring
within 6 months. Because it is difficult to make a clinical decision
based on delayed irAE, we suppose that irAE occurring at least
within 6 months would have clinical significance as a biomarker.Frontiers in Oncology | www.frontiersin.org 6A subgroup of patients who developed immune-related
hypothyroidism or vitiligo in the unfavorable group had longer
OS than other subgroups of patients (median, 43.6 vs. 13.1 months;
p=.008), although PFS was not significantly longer (median, 8.6 vs.
2.8 months; p=.199). The findings are supported by previous
studies. A systematic review showed that patients who developed
vitiligo were associated with two to four times less risk of disease
progression or death, respectively, compared to those without (11).
A prospective observational study of 67 melanoma patients showed
that an objective response to treatment was associated with a higher
incidence of vitiligo and all 17 patients who developed vitiligo were
alive at the time of analysis, which means that patients with vitiligo
had durable response. A retrospective study with 174 patients who
received ICB for metastatic or advanced cancers showed a
significantly longer PFS (median, 66 vs. 27 weeks) and OSA B
C D
FIGURE 2 | Survival analyses among the unfavorable group (visceral/CNS metastasis or elevated baseline LDH level). (A) Overall survival and (B) progression-free
survival in patients who developed lymphopenia (<1000 cells/mL) within 3 months and those who did not. (C) Overall survival and (D) progression-free survival in
patients who developed immune-related adverse events (irAE; hypothyroidism or vitiligo) within 6 months and who did not.May 2021 | Volume 11 | Article 659754
Byun et al. Response Prediction in Melanoma(median, 156 vs. 59 weeks) in the thyroid dysfunction group than
in the euthyroid group (10). As this group had an extremely long
survival even after disease progression, we named the group “late
responders.” The subsequent treatments after ICB monotherapy
had a long-term response (Supplementary Table 1). We did not
elucidate whether the long-termOS was attributed to the irAE itself
or the good treatment response. If the former is correct, irAE would
be a prognostic factor, and if the latter is correct, irAE would be a
predictive factor. Further study regarding this issue is warranted.
Using a simple decision tree, we suggested an optimal way to
apply these factors in the clinical decision making in a time
dependent manner. Nosrati et al. (20) developed a clinical scoring
system to predict response to anti-PD-1 monotherapy in patients
with advanced melanoma. The variables used in the scoring
system were baseline clinical factors, such as sex, age, previous
ipilimumab treatment, elevated LDH, and liver metastasis. Our
model is practical in that it is not only simple but also includes
variables of multiple time points, such as baseline, 3 months, and
6 months. This model has strength in that it can be applied before
ICB monotherapy and during early ICB monotherapy.
Our study is retrospective in nature and therefore is limited
by the presence of uncontrolled confounding factors, variations
in ICB therapy cycles, variable radiation doses/sites, and under-
reporting of toxicity. In addition, information regarding date of
progression on ICB was not uniformly assessed because it would
have been on a prospective clinical trial. Thus, we focused mainly
on OS given the atypical patterns of response that can be
observed after ICB therapy. Moreover, the sample size was
relatively small. However, we collected a homogenous cohort
of patients with advanced melanoma who received ICB therapy
at a single institution. As the sample size was small, the
correlation between the biomarkers and survival outcomes did
not imply causation. Therefore, our findings need to be furtherFrontiers in Oncology | www.frontiersin.org 7validated using a larger global data set. Furthermore, irAE was
significant in the univariable analysis for OS, but it lost its
significance in the subsequent multivariable analysis, which
may be due to the small number of groups. Additionally, these
patients had stage IV or unresectable disease, so they did not
undergo surgery or biopsy at the time of immunotherapy.
Therefore, there was no tumor sample available at the time of
immunotherapy to show molecular data or pathological images.
We are currently conducting a prospective phase II trial on the
efficacy of a combination of immunotherapy and radiotherapy
for treating melanoma (NCT 04017897). In this trial, we are
collecting blood samples, tumor tissues, and stool samples from
participants and planning to analyze them.
In conclusion, we suggested a clinical predictive model using
easily accessible clinical indicators to predict treatment outcomes
in patients with advanced or metastatic melanoma who received
ICB monotherapy. These indicators are baseline LDH level,
visceral/CNS metastasis, lymphopenia within 3 months, and
hypothyroidism or vitiligo within 6 months. Although these
indicators have been reported as prognostic factors separately
in previous reports, we showed that all were independent
prognostic factors in a patient cohort, which add to the
growing body of literature. The identification of a clinical
predictive model is critical due to the following reasons. Firstly,
it allows patients who are unlikely to benefit from anti-PD-1
therapy to be spared from unnecessary risk of toxicity and to
rationally select a combination that will better fit them. Secondly,
it can spare those who are likely to respond to PD-1
monotherapy from unnecessary toxicities from combination
immunotherapy approach. This model could potentially have a
role in the therapeutic decision-making and proper patient
selection regarding immunotherapy. Its validation in future
studies is warranted.A B
FIGURE 3 | (A) Proposed decision tree to predict patients who may benefit from immune checkpoint blockade; it was used to determine the four risk groups:
favorable group (patients with normal baseline LDH level and no CNS/visceral metastasis; group A), unfavorable group (patients with elevated baseline LDH level or
CNS/visceral metastasis) without lymphopenia within 3 months (group B), unfavorable group with lymphopenia within 3 months (group C), and late responders
(unfavorable group with immune-related hypothyroidism or vitiligo within 6 months; group D) (B) Overall survival according to the four risk groups.May 2021 | Volume 11 | Article 659754
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